Gilead Sciences Inc. announced final results from the Phase 3 MYR301 study, highlighting the effects of bulevirtide as a treatment for chronic hepatitis delta virus $(HDV)$. The study revealed that 36% of adults treated with bulevirtide maintained virologic suppression for nearly two years after stopping treatment, having achieved undetectable HDV RNA at the end of treatment. The data also showed that 90% of those who achieved undetectability at 96 weeks of treatment remained undetectable for almost two years post-treatment. Bulevirtide, available in a 2 mg dose, is currently approved in the European Economic Area, the UK, Switzerland, and Australia, but not in the U.S. The findings underscore the potential of bulevirtide to provide a durable response and improve outcomes for individuals living with chronic HDV.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.